Delving into the Latest Updates on ADERIS Pharmaceuticals, Inc. with Synapse

概览

关联

8

项与 ADERIS Pharmaceuticals, Inc. 相关的药物

DTI-0017

靶点

A1R

作用机制

A1R拮抗剂

在研机构-

原研机构

ADERIS Pharmaceuticals, Inc.

在研适应症-

非在研适应症

心脏衰竭

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

WRC 0571

靶点

A1R

作用机制

A1R拮抗剂

在研机构-

原研机构

ADERIS Pharmaceuticals, Inc.

在研适应症-

非在研适应症

心血管疾病 [+1]

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

WRC-0342

靶点

A1R

作用机制

A1R拮抗剂

在研机构-

原研机构

ADERIS Pharmaceuticals, Inc.

在研适应症-

非在研适应症

心血管疾病

最高研发阶段终止

首次获批国家/地区-

首次获批日期-

1

项与 ADERIS Pharmaceuticals, Inc. 相关的临床试验

NCT00040001

/ Completed临床2期

Safety and Efficacy Study of an A1-Adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation

This study is designed to evaluate the safety of DTI-0009 in patients with atrial fibrillation and to find the dose of DTI-0009 that lowers heart rates in patients with atrial fibrillation with rapid ventricular response.

开始日期-

申办/合作机构

ADERIS Pharmaceuticals, Inc.

100 项与 ADERIS Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 ADERIS Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

13

项与 ADERIS Pharmaceuticals, Inc. 相关的文献（医药）

1999-01-01·IDrugs : the investigational drugs journal

Adenosine agonists for the prevention of restenosis?

Article

作者: Martin, P L

Balloon angioplasty involves the simultaneous activation of platelets and neutrophils. Activated platelets release mitogenic substances that cause smooth muscle cell proliferation and thereby contribute to restenosis. Activated neutrophils activate platelets and activated platelets activate neutrophils. Therefore the simultaneous activation of both cell types may be responsible for the exaggerated repair mechanisms resulting in restenosis of coronary blood vessels. Adenosine inhibits neutrophil activation, platelet activation and smooth muscle cell proliferation and stimulates endothelial cell proliferation predominantly through activation of A2A-receptors. Adenosine and A2A-selective agonists may be useful in the prevention of restenosis following balloon angioplasty.

1998-01-01·Developments in Cardiovascular Medicine

Vascular Biology and Pharmacology of Adenosine Receptors

作者: Martin, Pauline L. ; Olsson, Ray A.

A review with many references

1997-10-01·Drug Development Research

Pharmacology and toxicology of the A2A-adenosine receptor agonist 2- [(cyclohexylmethylene)hydrazino]adenosine (MRE-0470) in the rat

作者: Barrett, R. J. ; Sykes, A. ; Martin, Pauline L. ; Mossem, D. ; Wright, K. F. ; Droppleman, D. A.

2-[(Cyclohexylmethylene)hydrazino]adenosine (MRE-0470) is an A_2A-adenosine receptor agonist that is a potent and selective coronary vasodilator.As part of a preclin. program, the pharmacol. and toxicol. of MRE-0470 have been studied in the rat.In isolated vas deferens, MRE-0470 activated A_2B receptors (EC₅₀ = 6.3 nM) and at higher concentrations activated A_2B receptors (EC₅₀ = 13 μM).In atrial tissues, MRE-0470 produced neg. inotropic and chronotropic actions through activation of A₁ receptors (EC₅₀ ∼ 9 μM).MRE-0470 produced no pos. inotropic or chronotropic actions in atrial or ventricular tissues.In anesthetized, reflex-blocked rats, MRE-0470 produced a decrease in hindquarter perfusion pressure (A₂: ED₅₀ = 0.31 μg) and a decrease in heart rate (A₁: ED₅₀ = 620 μg).In conscious rats, MRE-0470 (0.04-117 μ/kg bolus or 0.03-150 μ/kg/min infusion) produced dose-dependent hypotension and reflex tachycardia.MRE-0470 was rapidly eliminated from rat plasma with an elimination half-life of 10 min.In toxicol. studies, once per day 10-min i.v. infusions of 3, 30, or 150 μg/kg/min MRE-0470 for 14 consecutive days resulted in no deaths and no changes in blood chem., but resulted in decreased motor activity and dose-related cardiomyopathy.Cardiomyopathy did not occur following single doses of MRE-0470.The incidence of this lesion is related to the duration of the repeated reflex tachycardia.These studies show that MRE-0470 is a potent and selective A_2A receptor agonist in the rat.The observed toxicol. of MRE-0470 is consistent with the exaggerated pharmacol. due to high-dose drug administration.

100 项与 ADERIS Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 ADERIS Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年05月07日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

其他

8

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

N-0861 ( A1R )	心肌梗塞更多	终止
DTI-0017 ( A1R )	心脏衰竭更多	终止
WRC-0342 ( A1R )	心血管疾病更多	终止
WRC-0542 ( A1R )	心血管疾病更多	终止
DTI-0026 ( LT )	肾小球肾炎更多	终止